<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02320604</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 14.04</org_study_id>
    <nct_id>NCT02320604</nct_id>
  </id_info>
  <brief_title>Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN)</brief_title>
  <official_title>Pharmacokinetics of Liposomal Amphotericin B (AmBisome®) Given Intravenously to Patients Undergoing Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dosing guidelines for liposomal amphotericin B (AmBisome) in (morbidly) obese patients are
      not available. Subsequently, the pharmacokinetic profile of AmBisome in this specific patient
      population is still largely unknown.

      To build a valid pharmacokinetic model, obese patients with a BMI ≥ 40 undergoing endoscopic
      gastric bypass surgery will receive a single dose of 1 mg/kg or 2 mg/kg AmBisome (besides
      standard anti-bacterial prophylaxis) and a PK-curve will be drawn. These PK-values can then
      be compared to the pharmacokinetics of a normal-weight group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The overall trial design is a prospective, open-label, non-randomized, single-centre,
           single-dose, multiple dose level trial, (1 mg/kg and 2 mg/kg).

        -  A total of sixteen patients with a BMI ≥40 kg/m2 undergoing bariatric surgery who
           receive a pre-surgery dose of AmBisome 1 mg/kg (n=8) or 2 mg/kg (n=8) will be enrolled.

        -  After enrollment of group 1 (1 mg/kg), an interim analysis on the safety of AmBisome
           will be performed before proceeding to group 2 (2 mg/kg).

        -  Infusion time and concentration of AmBisome will be 45 minutes (1 mg/kg group) and 90
           minutes (2 mg/kg group)

        -  A PK curve will be determined after administration of a single, pre-surgery dose of
           AmBisome at t = 0.5, 0.75 (end of infusion group 1), 1.5 (end of infusion group 2), 2,
           4, 6, 8, 10, 12, 24, 36, and 48 and (if feasible) 72 hours post infusion (n=12 samples)
           for group 1 (1 mg/kg), 8 patients.The PK curve of group 2 (2 mg/kg, 8 patients) will be
           similar to group 1, except for the t=1.5 hour sampling point, which will be end of
           infusion due to the infusion time of 90 minutes.

        -  Patients are considered to have completed the study if at least 9/11 samples of the PK
           curve up until 48 hours have been collected.

        -  Patients will be selected by the research team to have a good spread in weight bands.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC) 0-inf Ambisome</measure>
    <time_frame>at t = 0.5, 0.75, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 and (if feasible) 72 hours post infusion</time_frame>
    <description>The primary outcome measurement will be the area under the plasma concentration-time curve (AUC) from time 0 to infinitive (inf) post infusion (AUC0- inf) value of AmBisome. This will be determined by use of the log-linear trapezoidal rule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) Ambisome</measure>
    <time_frame>at t = 0.5, 0.75, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 and (if feasible) 72 hours post infusion</time_frame>
    <description>Peak concentration over the sampling interval.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Obese Subjects 1mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 obese subjects will receive 1mg/kg Ambisome i.v. infused over 45 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese Subjects 2mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 obese subjects will receive 2mg/kg Ambisome i.v. infused over 90 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of study drug</intervention_name>
    <description>i.v. administration of Ambisome in two different dossages</description>
    <arm_group_label>Obese Subjects 1mg/kg</arm_group_label>
    <arm_group_label>Obese Subjects 2mg/kg</arm_group_label>
    <other_name>Ambisome</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has a BMI ≥40 kg/m2 and is undergoing bariatric surgery

          2. Subject is at least 18 of age on the day of screening.

          3. Subject or legal representatives are able and willing to sign the Informed Consent
             before screening evaluations.

        Exclusion Criteria:

          1. Documented history of sensitivity to medicinal products or excipients similar to those
             found in the polyene preparation.

          2. History of, or current abuse of drugs, alcohol or solvents (up until a maximum of
             three months before enrolment).

          3. Inability to understand the nature of the trial and the procedures required.

          4. Administration of nephrotoxic medication (aminoglycosids, immunosuppressants,
             antivirals, antineoplastic agents) up until a maximum of one month before enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roeland E Wasmann, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roger JM Brüggemann, PharmD, PhD</last_name>
    <phone>0031243616405</phone>
    <email>Roger.Brüggemann@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roeland E Wasmann, PharmD</last_name>
    <phone>0031243616405</phone>
    <email>Roeland.Wasmann@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Antonius hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Knibbe, PharmD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>B van Ranshorst</last_name>
    </contact_backup>
    <investigator>
      <last_name>C Knibbe, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2014</study_first_submitted>
  <study_first_submitted_qc>December 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2014</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liposomal amphotericin B</keyword>
  <keyword>AmBisome</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Obesity</keyword>
  <keyword>Bariatric surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan has been made. Individual researchers are welcome to request data with our group.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

